Curaleaf International, in Partnership with Jupiter Research, Secures EU Medical Device Certification for Europe's First Handheld Liquid Inhalation Device
MWN-AI** Summary
Curaleaf International, a subsidiary of Curaleaf Holdings, Inc. (TSX: CURA), has achieved a significant milestone by securing EU medical device certification for Europe’s first handheld liquid inhalation device in collaboration with Jupiter Research LLC, a subsidiary of TILT Holdings Inc. (Cboe CA: TILT). This certification, classified as a Class IIa medical device under Regulation (EU) 2017/745, represents a breakthrough in the medical cannabis field, paving the way for enhanced patient care and innovative cannabis delivery solutions.
The newly certified inhalation device is engineered to provide accurate cannabinoid dosing through a magnetic snap-in cartridge and rechargeable power supply, ensuring reliable and controlled delivery for patients. The rigorous assessment process included the creation and approval of a comprehensive technical file and an EU Declaration of Conformity, confirming the device's quality, safety, and clinical efficacy.
Once commercialized, this device will be available in various markets, including the UK, Canada, and countries across Europe and Australasia, enabling healthcare professionals to adopt a novel treatment option for patients. Both Boris Jordan, Chairman and CEO of Curaleaf, and Tim Conder, CEO of TILT, highlighted the importance of this achievement, emphasizing its role in integrating medical cannabis into mainstream healthcare and revolutionizing patient treatment options through technological advancement.
Curaleaf International is committed to advancing the accessibility of legal, high-quality cannabis treatments globally. Their extensive distribution network, including facilities in the UK, Portugal, Spain, Germany, and Poland, reinforces their dedication to quality and innovation in the cannabis sector.
MWN-AI** Analysis
Curaleaf International has recently achieved a significant milestone by securing EU medical device certification for its handheld liquid inhalation device, in collaboration with Jupiter Research. This development positions Curaleaf at the forefront of medical cannabis delivery innovation in Europe and could potentially transform patient care and access to cannabis treatments in key international markets, including the UK, Canada, and Australasia.
From an investment perspective, this FDA approval represents not only a regulatory achievement but also opens the door to expanded global market opportunities. The device's Class IIa certification indicates that it meets stringent safety and quality standards, which should enhance consumer trust and foster partnerships with healthcare professionals. Curaleaf's robust distribution network, combined with the innovative technology of its inhalation device, allows it to capitalize on the growing demand for patient-centric cannabis solutions.
The collaboration with Jupiter Research is pivotal, showcasing the synergy between technology and healthcare that can drive growth in the cannabis sector. Moving forward, as the healthcare community increasingly recognizes the legitimacy of cannabis treatments, Curaleaf’s product could gain acceptance among practitioners and patients, further increasing its market penetration.
Investors should consider Curaleaf International’s proactive stance in bringing cutting-edge products to market, particularly as the cannabis industry matures. With regulatory challenges still present but slowly easing in many jurisdictions, Curaleaf is well-positioned for long-term growth.
In summary, Curaleaf International's recent achievement is a strong indicator of its potential for future growth, driven by innovation and enhanced market positioning. While market conditions can fluctuate, the company’s focus on research, product development, and global expansion makes it a compelling consideration for investors looking to enter or expand their presence in the cannabis industry.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Canada NewsWire
LONDON , May 12, 2025 /CNW/ -- Curaleaf International, part of Curaleaf Holdings, Inc. (TSX: CURA) in collaboration with Jupiter Research LLC, a subsidiary of TILT Holdings Inc. ("TILT") (Cboe CA: TILT) (OTCPK: TLLTF), has secured regulatory approval for the first handheld liquid inhalation device designed for precise medical cannabis administration. This EU medical device certification (Regulation (EU) 2017/745) paves the way for improved patient options and a new era of innovation in medical cannabis delivery.
The liquid inhalation device is now certified as a Class IIa medical device, meeting rigorous European regulatory standards. The device includes a magnetic snap-in cartridge and a rechargeable power supply, engineered to provide a consistent and controlled cannabinoid delivery. A comprehensive technical file and full EU Declaration of Conformity were assessed and approved by a recognised EU Notified Body, validating the device's quality, safety, and clinical robustness.
EU certification supports deployment in multiple global markets and once commercialised, will enable healthcare professionals to recommend the device offered by Curaleaf International in countries including European countries, the UK, Canada , and regions across Australasia.
Boris Jordan , Chairman and CEO of Curaleaf, commented on this achievement:
"Achieving EU medical certification is more than a regulatory milestone—it's a signal that medical cannabis innovation is moving into the mainstream of global healthcare. We're proud to offer a device that meets the highest standards of safety and quality, and we look forward to supporting patients and healthcare providers across Europe and beyond with a new, accurate and discrete option for treatment."
Echoing this sentiment, TILT's Chief Executive Officer Tim Conder , added:
"Partnering with Curaleaf International on this project has been a natural extension of our long-standing partnership in the US. By delivering industry-leading, user-friendly solutions, our collaboration exemplifies how technology can revolutionise healthcare. Achieving EU medical certification on IP developed by our subsidiary Jupiter Research, validates the robustness of our engineering and R&D functions and sets a new benchmark for the industry."
This development reinforces Curaleaf International's role at the forefront of advancing access to legal, high-quality cannabis treatments across Europe and other international markets.
About Curaleaf International
Curaleaf International is shaping the future of cannabis through its commitment to research and product excellence. Powered by a strong presence at all stages of the supply chain, its unique distribution network throughout Europe , Canada and Australasia brings together pioneering research with cutting-edge cultivation, extraction, and production. Amidst a rapid growth trajectory, the emphasis on quality and expertise aims to ensure the delivery of safe and legal cannabis.
Curaleaf International's network includes a clinic, pharmacy, and laboratory in the UK; cultivation and EU-GMP processing facilities in Portugal ; an EU-GMP processing, quality assurance and research site in Spain ; Four20 Pharma wholesaler and distributor in Germany ; a Polish wholesaler and clinic; and the EU-GMP producer Northern Green Canada.
Curaleaf International is part of Curaleaf Holdings, Inc., a leading international producer and distributor of consumer cannabis products.
About TILT and Jupiter Research
TILT Holdings manages a diverse portfolio of companies in the cannabis industry, encompassing technology, hardware, cultivation, and production. Its core business, Jupiter Research LLC , is a wholly owned subsidiary and a global distribution leader in the vaporization segment. Jupiter is dedicated to hardware design, research, development, and distribution to support cannabis brands and retailers across the United States , Canada , South America , and the European Union. Additionally, TILT is a multi-state operator, with cultivation and production facilities in three states under the Commonwealth Alternative Care and Standard Farms brands. For more information, visit www.tiltholdings.com .
Media Contact:
Curaleaf International:
Beth Sweet-Escott
Head of Communications, Curaleaf International
media@curaleafint.com
TILT:
Lynn Ricci
VP of Investor Relations & Corporate Communications, TILT Holdings Inc.
lricci@tiltholdings.com
SOURCE Curaleaf International
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/May2025/12/c6287.html
FAQ**
How will Curaleaf International's new handheld liquid inhalation device, now certified under EU regulations, impact its market share in the EU cannabis sector, considering its stock symbol Cura:Cc CURA:CC?
What are the anticipated commercial strategies for Curaleaf International to promote its newly certified inhalation device in target markets like Canada, given the framework of its operations under Cura:Cc CURA:CC?
With Curaleaf International's recent EU medical device certification, what collaborative opportunities do they foresee arising from their partnership with Jupiter Research in furthering cannabis-related innovations, as reflected in Cura:Cc CURA:CC?
Given the rigorous standards for EU medical device certification, how does Curaleaf International plan to ensure ongoing compliance and product quality for the handheld inhalation device, and what implications does this have for investors in Cura:Cc CURA:CC?
**MWN-AI FAQ is based on asking OpenAI questions about TILT HOLDINGS INC. (AQNC: TILT:CC).
NASDAQ: TILT:CC
TILT:CC Trading
1.92% G/L:
$0.265 Last:
72,232 Volume:
$0.26 Open:
